American Society of Hirudotherapy

Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study

Substudy of a randomized controlled trial with a non-randomized registry arm published in Catheter Cardiovasc Interv (2019)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Randomized controlled trialDrug DevelopmentClinical LiteratureGarcia-Garcia HM et al. · Catheter Cardiovasc Interv, 2020

Abstract

BACKGROUND: Residual stent strut thrombosis after primary percutaneous coronary intervention (PCI), negatively affects myocardial perfusion, may increase stent thrombosis risk, and it is associated with neointima hyperplasia at follow-up. OBJECTIVES: To study the effectiveness of any bivalirudin infusion versus unfractionated heparin (UFH) infusion in reducing residual stent strut thrombosis in patients with ST-elevation myocardial infarction (STEMI). METHODS: Multi-vessel STEMI patients undergoing primary PCI and requiring staged intervention were selected among those randomly allocated to two different bivalirudin infusion regimens in the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) Treatment-Duration study. Those receiving heparin only were enrolled into a registry arm. Optical coherence tomography (OCT) of the infarct-related artery was performed at the end of primary PCI and 3-5 days thereafter during a staged intervention. The primary endpoint was the change in minimum flow area (ΔMinFA) defined as (stent area + incomplete stent apposition [ISA] area) - (intraluminal defect + tissue prolapsed area) between the index and staged PCI. RESULTS: 123 patients in bivalirudin arm and 28 patients in the UFH arm were included. Mean stent area, percentage of malapposed struts, and mean percent thrombotic area were comparable after index or staged PCI. The ΔMinFA in the bivalirudin group was 0.25 versus 0.05 mm2 in the UFH group, which resulted in a between-group significant difference of 0.36 [95% CI: (0.05, 0.71); p = .02]. This was mostly related to a decrease in tissue protrusion in the bivalirudin group (p = .03). There was a trend towards more patients in the bivalirudin group who achieved a 5% difference in the percentage of OCT frames with the area >5% (p = .057). CONCLUSIONS: The administration of bivalirudin after primary PCI significantly reduces residual stent strut thrombosis when compared to UFH. This observation should be considered hypothesis-generating since the heparin-treated patients were not randomly allocated.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleMulticenter StudyRandomized Controlled Trial
Indexed MeSH termsAgedAnticoagulantsAntithrombinsCoronary ThrombosisFemaleHemorrhageHeparinHirudinsHumansInfusions, ParenteralItalyMaleMiddle AgedNeointimaPeptide FragmentsPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesRecombinant ProteinsST Elevation Myocardial InfarctionStentsTime FactorsTomography, Optical CoherenceTreatment Outcome

Summary

In a MATRIX substudy of 123 bivalirudin and 28 UFH STEMI patients, OCT imaging showed that bivalirudin produced a larger increase in minimum flow area than UFH (0.25 vs 0.05 mm²), suggesting reduced residual stent thrombosis.

Why This Matters for Hirudotherapy

This MATRIX OCT sub-study examined whether bivalirudin infusion reduced residual stent strut thrombosis compared to unfractionated heparin in STEMI patients (123 bivalirudin, 28 heparin registry) undergoing primary PCI, using optical coherence tomography to measure changes in minimum flow area. Bivalirudin is a synthetic direct thrombin inhibitor structurally derived from hirudin, the potent anticoagulant in medicinal leech saliva, illustrating how a leech-secretome-inspired agent performs in modern interventional cardiology. The study found a significantly greater improvement in minimum flow area with bivalirudin (between-group difference 0.36 mm², p = .02), mainly due to decreased tissue protrusion. However, these findings should be considered hypothesis-generating because heparin-treated patients were not randomly allocated, and the study does not speak to leech therapy itself but rather to a pharmaceutical analog of a leech-derived compound.

Citation

Reference (Vancouver style)

Garcia-Garcia HM, Adamo M, Soud M, Yacob O, Picchi A, Sardella G, et al. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study. Catheter Cardiovasc Interv. 2020;96(6):1156-1171. doi:10.1002/ccd.28661. PMID: 31883294

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.